Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings Of The Fortnight Sees New Biotech Funding All Over The Globe, And Without Much VC Participation

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus news on recent financial activity by Merrimack, Promethera, ADC Therapeutics and Enterome Bioscience.

You may also be interested in...



Financings Of The Fortnight: In The Aftermath Of Facebook IPO, Kythera Steps Up, TVAX And Cancer Genetics Back Off

Plus news on recent financing activity by TVM Capital, Royalty Pharma, Prosonix and Sangart.

Lilly And Canadian VCs To Fund TVM Life Sciences VII To Develop Single-Asset Companies

Lilly and Canadian VCs back a new TVM Life Sciences fund that will invest in a network of single-asset companies in Quebec.

New $80 Million U.K. Asset-Centric Cancer Research Fund Set Up With EU, Charity Funding

The U.K.'s Cancer Research Technology and the European Investment Fund join forces to launch an asset-centric investment fund to bridge the development gap, the third new U.K. fund in two weeks.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073987

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel